Lexeo Therapeutics (LXEO) Net Equity Issued and Repurchased (2025 - 2026)
Lexeo Therapeutics (LXEO) reported Net Equity Issued and Repurchased of $143000.0 for Q1 2026, down 15.88% on a YoY basis from $170000.0 in Q1 2025, and up 14400.0% sequentially from -$1000.0 in Q4 2025.
Lexeo Therapeutics (LXEO) Net Equity Issued and Repurchased (2025 - 2026) Analysis & Trends
Lexeo Therapeutics (LXEO) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $143000.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Equity Issued and Repurchased fell 15.88% year-over-year to $143000.0; the trailing twelve-month figure through Mar 2026 stood at $243000.0 (changed N/A YoY), and the FY2025 full-year result was $270000.0, changed N/A from the prior year.
- Net Equity Issued and Repurchased rose to $143000.0 in Q1 2026, from -$1000.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $170000.0 in Q1 2025 to a low of -$1000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 141.90 Mn |
| 10 | Lexeo Therapeutics | 379.94 Mn | 379.94 Mn | - | 143,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143,000.00 |
| Mar 31, 2026 | 143,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | 101,000.00 |
| Sep 30, 2025 | 101,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Mar 31, 2025 | 170,000.00 |